Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA5A | P35218 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL5094785 | 0.89 | GRIA1 (0.39) | CA2CA5ACA1CA9KIF11 | |
| SCHEMBL13144458 | 0.88 | ALDH1A1 (0.42) | CA2CA5ACA1CA9KIF11 | |
| SCHEMBL3116170 | 0.86 | MAPT (0.34) | CA2CA5AKMT2AMEN1MAPT | |
| SCHEMBL6993736 | 0.85 | MEN1 (0.41) | KIF11KMT2AMEN1MAPTALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL9420028 | 0.84 | KIF11 (0.38) | CA2CA5ACA1CA9KIF11 | |
| SCHEMBL10432083 | 0.82 | KIF11 (0.43) | KIF11KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL356010 | 0.81 | LMNA (0.33) | KMT2A | |
| Trifluoromethanesulfonic Acid SCHEMBL9419957 | 0.77 | CASP6 (0.40) | CA2CA5ACA1CA9KIF11 | |
| SCHEMBL3116165 | 0.75 | HPGD (0.36) | CA2CA5AKMT2AMEN1MAPT | |
| SCHEMBL13304950 | 0.75 | S100A4 (0.38) | KIF11KMT2AHTTMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | disclosed |
| EP-2144893-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2074107-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008137816-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008057254-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-0647638-B1 | (HALOALKYL)DIBENZO-ONIUM SULFONATE, PROCESS FOR PRODUCING THE SAME, AND HALOALKYLATING AGENT AND METHOD | DAIKIN IND LTD (JP) | 1998-10-07 | — | — | EP | disclosed |
| US-5569771-A | (Haloalkyl) dibenzooniumsulfonate and its production methods; and a haloalkylating agent and haloalkylating methods | DAIKIN INDUSTRIES LTD. (JP) | 1996-10-29 | — | — | US | disclosed |
| EP-0647638-A1 | (HALOALKYL)DIBENZO-ONIUM SULFONATE, PROCESS FOR PRODUCING THE SAME, AND HALOALKYLATING AGENT AND METHOD | DAIKIN INDUSTRIES, LIMITED (JP) | 1995-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP13, MMP2, MMP12 | CA2 345/4885CA5A 277/4885CA1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.